Script section containing code for Liveperson Chat Solution

Hoover's - A D&B Company - We Make It Easier
I'm Ready to Subscribe
Special Offers
DNBi. Leverage D&B's credit assessment tools.

H. Lundbeck A/S · Copenhagen Denmark (OMX Copenhagen: LUN)

Ottiliavej 9Phone: +45-36-30-13-11
CopenhagenFax: +45-36-30-19-40
DK-2500
DenmarkMap Map This Company
  • Company Profiles
  • Competitive Landscapes
  • Industry Reports

Buy Reports

For a Hoover's Free Trial, Call
(866) 444-8642
or
Chat Now

H. Lundbeck A/S Rankings

Company Description

The health of the nervous system is central to H. Lundbeck's business plan. H. Lundbeck develops medicine primarily for the treatment of diseases of the central nervous system. Sold throughout the world, Lundbeck's main products include Cipralex (licensed to Forest Laboratories in the US market under the brand Lexapro) for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer's disease, and Azilect for the treatment of Parkinson's disease. Lundbeck spends about 20% of its revenue on research and development. The company has additional licensing and collaborative agreements with other drug makers including Teva PharmaceuticalsTakedaMerz, and Solvay

To read the full description: Subscribe Now
left-headH. Lundbeck A/S Reports
right-head

No subscription, no problem.

Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.

Shop Reports
Shop Reports

Financials

Company TypePublic - OMX Copenhagen: LUN Headquarters
Fiscal Year-EndDecember
2010 Employees5,866
More H. Lundbeck A/S Financials

Executives

15 executives listed for H. Lundbeck A/S's Copenhagen, Denmark location.

ChairmanPer Wold-OlsenE-mail
Deputy ChairmanThorleif KrarupE-mail
CEOUlf WiinbergE-mail

More H. Lundbeck A/S Executives

Top H. Lundbeck A/S Competitors

Sponsored Links